Inactive Instrument

News GOLD SWAP OTC Bulletin Board

Stocks

GDSW

US38074W1009

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

09-18	Silo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd Treatment	CI
09-09	Silo Pharma Highlights Patented Nose-To-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum	CI

All News

Mentions Relevance

09-18	Silo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd Treatment	CI
09-18	Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio	AQ
09-09	Silo Pharma Highlights Patented Nose-To-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum	CI
09-09	Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum	AQ
08-19	Silo Pharma, Inc. acquired Certain software, technology, domain names, and related intellectual property of Parkview Consulting from Parkview Consulting Ltd for $0.51 million.	CI
08-18	Silo Pharma Gets Canadian Patent Allowance for Stress Disorder Treatment	MT
08-18	Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment	AQ
08-18	Silo Pharma Receives Notice of Allowance for Canadian Patent Application Covering Lead Asset Spc-15 Targeting Ptsd and Other Stress-Induced Psychiatric Disorders	CI
08-13	Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026.	CI
08-13	Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-10	Silo Pharma Granted European Patent Covering Novel PTSD Therapy	AQ
08-06	Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform	AQ
07-21	Silo Pharma Advances AI Agent Platform Toward Commercial Launch And Progresses Lead PTSD Drug Program SPC-15	CI
07-21	Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program	AQ
07-14	Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform	AQ
07-10	Top Midday Decliners	MT
07-10	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT
07-10	Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
07-09	Silo Pharma, Inc. announced that it has received $4.000015 million in funding	CI
07-07	Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program	AQ
06-29	Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request	AQ
06-29	Silo Pharma Advances SPC-15 PTSD Therapeutic With Drug-Device Robustness Study Ahead Of Planned FDA Type C Meeting Request	CI
06-23	Silo Pharma, Inc. Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-In-Human Clinical Trial	CI
06-23	Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months	MT
06-23	Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial	AQ